251 related articles for article (PubMed ID: 21362317)
1. Design of functional small interfering RNAs targeting amyotrophic lateral sclerosis-associated mutant alleles.
Geng CM; Ding HL
Chin Med J (Engl); 2011 Jan; 124(1):106-10. PubMed ID: 21362317
[TBL] [Abstract][Full Text] [Related]
2. Double-mismatched siRNAs enhance selective gene silencing of a mutant ALS-causing allele.
Geng CM; Ding HL
Acta Pharmacol Sin; 2008 Feb; 29(2):211-6. PubMed ID: 18215350
[TBL] [Abstract][Full Text] [Related]
3. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
[TBL] [Abstract][Full Text] [Related]
4. Designing siRNA that distinguish between genes that differ by a single nucleotide.
Schwarz DS; Ding H; Kennington L; Moore JT; Schelter J; Burchard J; Linsley PS; Aronin N; Xu Z; Zamore PD
PLoS Genet; 2006 Sep; 2(9):e140. PubMed ID: 16965178
[TBL] [Abstract][Full Text] [Related]
5. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
[TBL] [Abstract][Full Text] [Related]
6. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.
Xia X; Zhou H; Huang Y; Xu Z
Neurobiol Dis; 2006 Sep; 23(3):578-86. PubMed ID: 16857362
[TBL] [Abstract][Full Text] [Related]
7. siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme.
Yokota T; Miyagishi M; Hino T; Matsumura R; Tasinato A; Urushitani M; Rao RV; Takahashi R; Bredesen DE; Taira K; Mizusawa H
Biochem Biophys Res Commun; 2004 Jan; 314(1):283-91. PubMed ID: 14715277
[TBL] [Abstract][Full Text] [Related]
8. In vivo application of an RNAi strategy for the selective suppression of a mutant allele.
Kubodera T; Yamada H; Anzai M; Ohira S; Yokota S; Hirai Y; Mochizuki H; Shimada T; Mitani T; Mizusawa H; Yokota T
Hum Gene Ther; 2011 Jan; 22(1):27-34. PubMed ID: 20649474
[TBL] [Abstract][Full Text] [Related]
9. [RNAi and neurological disease].
Yokota T
Rinsho Shinkeigaku; 2005 Nov; 45(11):973-5. PubMed ID: 16447777
[TBL] [Abstract][Full Text] [Related]
10. RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells.
Maxwell MM; Pasinelli P; Kazantsev AG; Brown RH
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3178-83. PubMed ID: 14981234
[TBL] [Abstract][Full Text] [Related]
11. Silencing strategies for therapy of SOD1-mediated ALS.
van Zundert B; Brown RH
Neurosci Lett; 2017 Jan; 636():32-39. PubMed ID: 27507699
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression.
Wang H; Ghosh A; Baigude H; Yang CS; Qiu L; Xia X; Zhou H; Rana TM; Xu Z
J Biol Chem; 2008 Jun; 283(23):15845-52. PubMed ID: 18367449
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi.
Ohnishi Y; Tamura Y; Yoshida M; Tokunaga K; Hohjoh H
PLoS One; 2008 May; 3(5):e2248. PubMed ID: 18493311
[TBL] [Abstract][Full Text] [Related]
14. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
Ralph GS; Radcliffe PA; Day DM; Carthy JM; Leroux MA; Lee DC; Wong LF; Bilsland LG; Greensmith L; Kingsman SM; Mitrophanous KA; Mazarakis ND; Azzouz M
Nat Med; 2005 Apr; 11(4):429-33. PubMed ID: 15768029
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.
Raoul C; Abbas-Terki T; Bensadoun JC; Guillot S; Haase G; Szulc J; Henderson CE; Aebischer P
Nat Med; 2005 Apr; 11(4):423-8. PubMed ID: 15768028
[TBL] [Abstract][Full Text] [Related]
16. [Gene therapy of ALS with short interfering RNA].
Yokota T
Brain Nerve; 2007 Oct; 59(10):1187-94. PubMed ID: 17969360
[TBL] [Abstract][Full Text] [Related]
17. Metal-deficient SOD1 in amyotrophic lateral sclerosis.
Hilton JB; White AR; Crouch PJ
J Mol Med (Berl); 2015 May; 93(5):481-7. PubMed ID: 25754173
[TBL] [Abstract][Full Text] [Related]
18. Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress.
Cookson MR; Menzies FM; Manning P; Eggett CJ; Figlewicz DA; McNeil CJ; Shaw PJ
Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Jun; 3(2):75-85. PubMed ID: 12215229
[TBL] [Abstract][Full Text] [Related]
19. Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs.
Hu J; Rigo F; Prakash TP; Corey DR
Nucleic Acid Ther; 2017 Apr; 27(2):87-94. PubMed ID: 28005462
[TBL] [Abstract][Full Text] [Related]
20. Short interfering RNA (siRNA) as a novel therapeutic.
Pushparaj PN; Melendez AJ
Clin Exp Pharmacol Physiol; 2006; 33(5-6):504-10. PubMed ID: 16700886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
